Effect Of Nanoparticle With Vascular Endothelial Growth Factor Gene Transfered Into Ischemic Myocardium

BackgroundVascular endothelial growth factor (VEGF) has been investigated for the treatment of ischaemic heart disease for more than a decade. A number of investigators have demonstrated the efficacy of angiogenic gene therapy for chronic myocardial ischaemia in animal studies and human trials. Most of the current VEGF gene therapy protocols use free DNA delivery or viral vector mediated systems. Viral and retroviral vectors have been the most efficient, but they may provoke mutagenesis and carcinogenesis. Plasmids are relatively non-toxic when used for gene transfer; however, their poor efficiency of delivery and unprotectedness against cellular surveillance systems have limited its clinical application.Biodegradable polymeric nanoparticles with entrapped plasmid DNA have shown the potential for achieving sustained gene expression. Nanoparticles are colloidal particles in the nanometer size range and contain a plasmid DNA of interest entrapped in their polymer matrix. Encapsulation of DNA in biodegradable polymer potentially offers a way to protect DNA from degradation...